Hereditary hemorrhagic telangiectasia

This phase 3 trial tests whether an experimental oral drug called engasertib can reduce the number of nosebleeds in adults with moderate to severe hereditary hemorrhagic telangiectasia (HHT), a genetic condition that causes abnormal blood vessels and frequent bleeding. About 240 …

This study is collecting information from 5,000 people with peripheral vascular disease who are being treated with Boston Scientific drug-eluting devices in everyday medical practice. The goal is to see how well these devices work and how safe they are in a wide range of patients…

This early-phase trial tests an experimental antibody called DIAG723 in 93 adults with hereditary hemorrhagic telangiectasia (HHT), a condition that causes abnormal blood vessels and frequent nosebleeds. The study will check if the drug is safe and how the body processes it, with…

This study tests an experimental drug called ATV-1601 in people with moderate to severe HHT, a condition that causes frequent nosebleeds and anemia. The trial has two parts: first, participants receive either the drug or a placebo to check safety and effectiveness; then, all elig…

This study follows 100 adults with hereditary hemorrhagic telangiectasia (HHT) who start taking blood thinners (anticoagulants or antiplatelets). Researchers compare the three months before treatment to the first three months on treatment, tracking bleeding events, iron levels, a…

This study tests a head-worn ultrasound device called SONAS that listens for bubble signals in the brain during a standard heart ultrasound. It aims to see if the device can accurately detect right-to-left shunts—abnormal connections between blood vessels—in adults with hereditar…

Hereditary hemorrhagic telangiectasia (HHT) causes tangled blood vessels that lead to frequent, hard-to-stop nosebleeds and low hemoglobin. Researchers are testing whether intravenous bevacizumab, given once or twice a year after nasal electrocoagulation, reduces nosebleed severi…

This study tests whether nintedanib, a drug already used for lung scarring, can reduce nosebleeds in people with hereditary hemorrhagic telangiectasia (HHT). About 48 adults with moderate to severe nosebleeds will take either nintedanib or a placebo twice daily for 16 weeks. The …

Researchers at University Hospital Essen are studying donated tissue from people with hereditary hemorrhagic telangiectasia (HHT), a genetic condition that causes abnormal blood vessel tangles called telangiectasias. The study compares tissue with and without these malformations,…

This study creates a detailed registry of people with hereditary hemorrhagic telangiectasia (HHT), a condition that causes abnormal blood vessels and bleeding. Researchers will track participants over time to collect information on symptoms, treatments, and disease progression. T…

This study creates a large registry of people diagnosed with hereditary hemorrhagic telangiectasia (HHT), a condition causing abnormal blood vessels and bleeding. Researchers will collect medical records and annual health updates for up to 10 years to understand how the disease c…

This study follows 400 pregnant women with rare blood vessel diseases (like HHT, Marfan syndrome, or lymphedema) to learn about serious pregnancy complications. Researchers will ask participants about their health during pregnancy and for 12 months after birth. The goal is to gat…

This study will use tiny probes called microdialysis to measure chemicals related to blood flow, inflammation, and antibiotics right inside the amputation stump after surgery. Researchers will compare results between diabetic and non-diabetic patients to understand why some stump…

This study is creating a large database to collect information on people with rare diseases like amyloidosis, sarcoidosis, and Gaucher disease. Researchers will track patients' health over time, including their symptoms, treatments, and outcomes. The goal is to improve diagnosis …

This study installs a 'black box' recording system in hybrid operating rooms to capture and analyze errors during vascular procedures. Researchers will study how teamwork, leadership, and the environment affect surgical performance and patient safety. The goal is to identify high…

This study looks at how iron supplements, often given for anemia, affect the immune system in people with Hereditary Haemorrhagic Telangiectasia (HHT), a rare genetic disorder that causes frequent nosebleeds and abnormal blood vessels. About 155 adults with HHT will be divided in…